Indaptus Posts $1.0M Q3 Loss, Pivots Toward Sleep-Device Research With $30.6M in Liquidity
INDP has more than doubled off its 52-week low of $0.92 on light trading volume (0.1× avg).
Summary
Indaptus reported a Q3 2026 net loss of about $1.0 million versus $3.0 million a year earlier, with R&D spending down 82% to roughly $0.3 million after the Decoy20 Phase 1 wind-down and headcount cuts. The company ended September 30 with about $26.6 million in cash plus $4.0 million in CDs, and collected the remaining $3.5 million of its $24.0 million private placement in October, which management says funds operations for at least a year. The bigger story is strategy: with no active clinical programs, the CEO is steering the company toward early-stage research on a neurotechnology and neural-network-based device for sleep-related conditions, with a possible future FDA submission. That is a speculative, pre-preclinical direction funded by heavy dilution — shares outstanding jumped to 133.2 million from 2.2 million at year-end 2025. The going-concern doubt is gone, but the equity story now rests on a sleep device concept rather than the Decoy immunotherapy platform.
At the time of this announcement, INDP was trading at $3.17 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $486.9M. The 52-week trading range was $0.92 to $5.96. This news item was assessed with neutral market sentiment and an importance score of 7 out of 10. Source: GlobeNewswire.